Results 11 to 20 of about 340 (125)

Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma. [PDF]

Cancer Rep (Hoboken)
ABSTRACT Background Uveal melanoma (UM) is the prevailing malignant tumor that develops within the eye in adults, and it has a bleak outlook because of the few treatment choices available and the high likelihood of returning after treatment. Currently, surgical intervention, radiation therapy, and a combination of both modalities are available ...
Azani A, Ghassemifar V, Mehrdad Z, Saberivand M, Bagheripour A, Tahmasebi S, Gharedaghi H, Sharafi M, Foroozand H, Soleimani Meigoli MS, Pourali S, Salmaninejad A, Ahmadi Beni F, Behfar Q.   +13 more
europepmc   +2 more sources

Early detection of metastatic uveal melanoma by the analysis of tumor-specific mutations in cell-free plasma DNA. [PDF]

Cancer Med, 2021
In metastasized uveal melanoma (UM) patients, circulating tumor DNA (ctDNA) can be detected in blood. Here we explored if cfDNA is a suitable biomarker for the early detection of metastatic disease in UM patients. Our data show that this biomarker fulfills the expectation as, overall, about half of the patients who developed metastases showed a ...
Le Guin CHD, Bornfeld N, Bechrakis NE, Jabbarli L, Richly H, Lohmann DR, Zeschnigk M.   +6 more
europepmc   +2 more sources

Current management of uveal melanoma: A review

Clinical &Experimental Ophthalmology, Volume 51, Issue 5, Page 484-494, July 2023., 2023
Abstract Uveal melanoma is the most frequent primary intraocular cancer in adulthood and is mostly localised to the choroid. It can be treated using radiation therapy, laser therapy, local resection and enucleation, with the best results achieved by combining these procedures. However, up to half of patients develop metastatic disease.
Haixia Bai, Jacobus J. Bosch, Ludwig M. Heindl   +2 more
wiley   +1 more source

Aggressive uveal melanoma displays a high degree of centrosome amplification, opening the door to therapeutic intervention

The Journal of Pathology: Clinical Research, Volume 8, Issue 4, Page 383-394, July 2022., 2022
Abstract Uveal melanoma (UM) is the most common intraocular cancer in adults. Whilst treatment of primary UM (PUM) is often successful, around 50% of patients develop metastatic disease with poor outcomes, linked to chromosome 3 loss (monosomy 3, M3). Advances in understanding UM cell biology may indicate new therapeutic options.
Dorota Sabat‐Pośpiech, Kim Fabian‐Kolpanowicz, Helen Kalirai, Natalie Kipling, Sarah E Coupland, Judy M Coulson, Andrew B Fielding   +6 more
wiley   +1 more source

Small High-Risk Uveal Melanomas Have a Lower Mortality Rate [PDF]

, 2021
Our aim was to determine whether size impacts on the difference in metastatic mortality of genetically high-risk (monosomy 3) uveal melanomas (UM). We undertook a retrospective analysis of data from a patient cohort with genetically characterized UM. All
Coupland, Sarah E, Damato, Bertil E, Eleuteri, Antonio, Groenewald, Carl, Heimann, Heinrich, Hussain, Rumana N, Kalirai, Helen, Taktak, Azzam FG   +7 more
core   +1 more source

Photodynamic Therapy in Ocular Oncology [PDF]

, 2020
Over the past two decades, we have witnessed the increasing use of photodynamic therapy (PDT) in the field of ocular oncology. Based on a review of the literature and our own experience, we herein review the role of PDT for the management of intraocular ...
Abtahi, Seyed-Hossein, Dalvin, Lauren A, Mashayekhi, Arman, Mazloumi, Mehdi, Shields, Carol L, Shields, Jerry A, Yaghy, Antonio, Yavari, Negin   +7 more
core   +5 more sources

New perspectives for eye-sparing treatment strategies in primary uveal melanoma [PDF]

, 2022
Uveal melanoma is the most common intraocular malignancy and arises from melanocytes in the choroid, ciliary body, or iris. The current eye-sparing treatment options include surgical treatment, plaque brachytherapy, proton beam radiotherapy, stereotactic
Bilmin K., Czarnecka A. M., Fiedorowicz M., Kujawska T., Merks P., Rejdak R., Solnik M., Spalek M. J., Synoradzki K. J., Toro M. D.   +9 more
core   +1 more source

Outcome Measures of New Technologies in Uveal Melanoma Review from the European Vision Institute Special Interest Focus Group Meeting [PDF]

, 2023
Uveal melanoma UM is the most common primary intraocular tumor in adults. New diagnostic procedures and basic science discoveries continue to change our patient management paradigms.
Beenakker, J. W.M., Brouwer, N.J., Chau, C., Coupland, S.E., Damato, B.E., Fiorentzis, M., Heimann, H., Heufelder, J., Jager, M.J., Joussen, A.M., Kiilgaard, J.F., Kivelä, T.T., Piperno Neumann, S., Rantala, E.S., Romanovska Dixon, B., Scholl, H.P.N., Shields, C.L., Wheeler Schilling, T., Willerding, G.D.   +18 more
core   +2 more sources

Widening use of dexamethasone implant for the treatment of macular edema [PDF]

, 2017
Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T., Bonfiglio V., Fallico M., Fichera S., Longo A., Macchi I., Pizzo A., Rapisarda C., Reibaldi M., Russo A.   +9 more
core   +2 more sources

Uveal Melanoma [PDF]

, 2021
Currently, melanoma of uvea is the most well-known essential tumor, which is intaocular and malignant. Treatment using radiation has now supplanted enucleation as the therapy of decision.
Furdova, Alena, Horkovicova, Kristina
core   +2 more sources